A clinicopathologic study revealed that approximately 50% of colon cancer patients had reduced expression of PITX1, and a significant correlation was observed between the low expression of PITX1 and shorter prognosis, worse staging, and more positive lymph node metastasis in colon cancer patients (29). Here, PITX1 is linked to malignant colon neoplasm.